GSA Capital Partners LLP Purchases 57,898 Shares of aTyr Pharma, Inc. (NASDAQ:ATYR)

Key Points

• GSA Capital Partners LLP increased its stake in aTyr Pharma, Inc. by 21.1%, purchasing an additional 57,898 shares during the first quarter, now owning a total of 332,324 shares valued at approximately $1,004,000.
• Shares of aTyr Pharma opened at $4.72, with a 1-year price range between $1.67 and $7.29, and a market capitalization of $420.08 million.
• Analysts have recently boosted aTyr Pharma's price targets, with Wells Fargo raising it to $25.00 and HC Wainwright issuing a target of $35.00, reflecting a strong positive outlook for the company.

GSA Capital Partners LLP increased its position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 21.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 332,324 shares of the company's stock after buying an additional 57,898 shares during the quarter. GSA Capital Partners LLP owned about 0.37% of aTyr Pharma worth $1,004,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of aTyr Pharma in the 4th quarter worth approximately $39,000. American Century Companies Inc. purchased a new position in shares of aTyr Pharma in the 4th quarter worth $319,000. JPMorgan Chase & Co. raised its position in shares of aTyr Pharma by 467.8% in the 4th quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock worth $646,000 after buying an additional 147,092 shares during the period. Diametric Capital LP acquired a new stake in aTyr Pharma in the 4th quarter valued at $108,000. Finally, Geode Capital Management LLC acquired a new stake in aTyr Pharma in the 4th quarter valued at $3,229,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

aTyr Pharma Price Performance

NASDAQ ATYR traded up $0.16 on Tuesday, reaching $5.18. The company's stock had a trading volume of 2,195,569 shares, compared to its average volume of 2,345,728. The firm has a market cap of $460.58 million, a PE ratio of -6.38 and a beta of 0.94. The business has a 50-day moving average price of $5.26 and a 200 day moving average price of $4.08. aTyr Pharma, Inc. has a 52 week low of $1.67 and a 52 week high of $7.29. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

ATYR has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company boosted their target price on aTyr Pharma from $17.00 to $25.00 and gave the stock an "overweight" rating in a report on Friday, June 20th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, aTyr Pharma currently has an average rating of "Buy" and a consensus price target of $20.20.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.